Send us a textWhat if controlling a single hormone in your brain could revolutionize the treatment of Alzheimer's and depression? On this episode of ASX Briefs, we're joined by Steve Gourlay, CEO of Actinogen Medical, a trailblazer in biotechnology, to unveil how their groundbreaking drug, Xanamem, could be a game-changer for mental health therapies. Steve takes us through Actinogen's fascinating journey from their 2014 merger with a University of Edinburgh startup to the promising Phase 2 depression trial results, where 167 patients showed significant improvement with minimal side effects.Steve demystifies the complex science behind Xanamem, explaining how it targets brain cortisol, a hormone infamous for its role in stress and cognitive decline. With a deep dive into the biology of the brain, Steve enlightens us on how selectively reducing cortisol in regions like the hippocampus and frontal cortex can prevent the detrimental effects of chronic stress on nerve cells. This episode is a must-listen for anyone interested in the future of mental health treatment and how innovative therapies are set to change the landscape.

Ver todos los episodios